HIGH-DENSITY-LIPOPROTEIN CONCENTRATION IS INCREASED DURING THE OVULATORY PHASE OF THE MENSTRUAL-CYCLE IN HEALTHY-YOUNG WOMEN

被引：13

作者：

AZOGUI, G ^{[1
]}

BENSHLOMO, I ^{[1
]}

ZOHAR, S ^{[1
]}

KOOK, A ^{[1
]}

PRESSER, S ^{[1
]}

AVIRAM, M ^{[1
]}

机构：

[1] REBECCA SIEFF GOVT HOSP,DEPT OBSTET & GYNECOL,IL-13100 SAFAD,ISRAEL

来源：

GYNECOLOGICAL ENDOCRINOLOGY | 1992年 / 6卷 / 04期

关键词：

SERUM LIPOPROTEINS; APOLIPOPROTEIN-A-I; APOLIPOPROTEIN-B; SEX HORMONES;

D O I：

10.3109/09513599209024987

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This study aimed to examine the relation between sex steroid hormone fluctuations during the menstrual cycle and serum lipoproteins and their constituents. Serum was obtained in the early follicular, preovulatory, and mid-luteal phases from 18 young women. Ovulation was confirmed by estrogen and progesterone assays. High density lipoprotein cholesterol (HDL-C) was found to increase by 16% in the preovulatory phase, in comparison to the early follicular phase. Serum apolipoprotein-AI (Apo-AI) was elevated in the preovulatory and mid-luteal phases (14% and 19%, respectively) in comparison to the early follicular phase. Total cholesterol, triglycerides, very low, and low density lipoprotein-cholesterol (VLDL-C and LDL-C) and apolipoprotein-B (Apo-B) serum levels did not change throughout the cycle. In the mid-luteal phase, the Apo-AI/HDL-C ratio was higher than in the other two phases, suggesting altered HDL composition during this phase. These results suggest that endogenous progesterone, unlike some synthetic progestogens, does not negate the beneficial effect of estrogen on serum lipoproteins.

引用

页码：253 / 257

页数：5

共 20 条

[1]

Bush T.L., Fried P.L., Barret-Connor E., Cholesterol, lipoproteins, and coronary heart disease in women, Clin. Chem, 34, (1988)

[2]

Kannel W., Hyordand M., McNamara P., Gordon T., Menopause and risk of cardiovascular disease — the Framingham study, Ann. Intern. Med, 5, (1976)

[3]

Paganini-Hill A., Ross R.K., Henderson B.E., Postmenopausal estrogen and stroke: a prospective study, Br. Med. J, 297, (1988)

[4]

Henderson B.E., Ross R.K., Paganini-Hill A., Mack T.M., Estrogen use and cardiovascular disease, Am. J. Obstet. Gynecol, 154, (1986)

[5]

Burch J.C., Byrd B.F., Vaughn W.K., The effects of long term estrogen on hysterectomized women, Am. J. Obstet. Gynecol, 118, (1974)

[6]

Bush T.L., Barret-Connor E., Non-contraceptive estrogen use and cardiovascular mortality, Circulation, 75, (1987)

[7]

Kuller L.H., Gutai J.P., Meilahn E., Matthews K.A., Plantinga P., Relationship of endogenous sex steroid hormones to lipids and apoproteins in postmenopausal women, Arteriosclerosis, 10, (1990)

[8]

Blumenfeld Z., Aviram M., Brook G., Brandes M., Changes in lipoproteins and subtractions following oophorectomy and estrogen replacement in perimenopausal women, Mauritas, 5, (1983)

[9]

Lobo P.A., Whitehead M., Too much of a good thing? Use of progestogens in the menopause: an international concencus statement, Fertil. Steril, 51, (1989)

[10]

Goudsland I.F., Crook D., Simpson R., Proudler T., Felton C., Lees B., Anyaoku V., Devenport M., Wynn V., The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism, N. Engl. J. Med, 323, (1990)

← 1 2 →